Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to DATROWAY® (datopotamab deruxtecan-dlnk) for ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Partial nephrectomy preserves renal function better than radical nephrectomy for complex tumors, especially in younger ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.